GoHealth Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GoHealth in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GoHealth stock.
View analyst ratings for GoHealth or view top-rated stocks.

Wall Street analysts have given GoHealth a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GoHealth wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

GoHealth saw a decrease in short interest in May. As of May 28th, there was short interest totaling 4,450,000 shares, a decrease of 15.6% from the May 13th total of 5,270,000 shares. Based on an average daily trading volume, of 1,560,000 shares, the short-interest ratio is presently 2.9 days. Approximately 4.5% of the company's stock are short sold.
View GoHealth's Short Interest.

GoHealth is scheduled to release its next quarterly earnings announcement on Thursday, August 19th 2021.
View our earnings forecast for GoHealth.

GoHealth, Inc. (NASDAQ:GOCO) issued its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.01. The business had revenue of $204.20 million for the quarter, compared to analyst estimates of $176.41 million. GoHealth had a positive trailing twelve-month return on equity of 13.15% and a negative net margin of 2.70%. The business's revenue for the quarter was up 44.8% compared to the same quarter last year.
View GoHealth's earnings history.

GoHealth issued an update on its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $1.15 billion-1.30 billion, compared to the consensus revenue estimate of $1.21 billion.

12 brokers have issued 12-month target prices for GoHealth's stock. Their forecasts range from $14.00 to $26.00. On average, they expect GoHealth's share price to reach $20.40 in the next twelve months. This suggests a possible upside of 79.9% from the stock's current price.
View analysts' price targets for GoHealth or view top-rated stocks among Wall Street analysts.

25 employees have rated GoHealth CEO Matthew Crummack on Glassdoor.com. Matthew Crummack has an approval rating of 90% among GoHealth's employees.

Some companies that are related to GoHealth include Equitable (EQH), Goosehead Insurance (GSHD), Ashmore Group (AJMPF), SelectQuote (SLQT), BRP Group (BRP), BRP Group (BRP), CorVel (CRVL), eHealth (EHTH), Fanhua (FANH), Huize (HUIZ), AA (AATDF), Tian Ruixiang (TIRX), The Marketing Alliance (MAAL), QDM International (QDMI) and Arista Investors (ARINA).
View all of GOCO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GoHealth investors own include Tesla (TSLA), Alibaba Group (BABA), CVS Health (CVS), Honeywell International (HON), Moderna (MRNA), Raytheon Technologies (RTX), Walmart (WMT), Cisco Systems (CSCO), Intel (INTC) and Johnson & Johnson (JNJ).

(GOCO) raised $750 million in an initial public offering (IPO) on Wednesday, July 15th 2020. The company issued 39,500,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, BofA Securities and Morgan Stanley served as the underwriters for the IPO and Barclays, Credit Suisse, Evercore ISI, RBC Capital Markets, William Blair, Cantor, SunTrust Robinson Humphrey and Loop Capital Markets were co-managers.

GoHealth trades on the NASDAQ under the ticker symbol "GOCO."

GoHealth's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (1.78%), River Road Asset Management LLC (1.68%), Credit Suisse AG (1.53%), BlackRock Inc. (1.37%), The Manufacturers Life Insurance Company (0.67%) and Millennium Management LLC (0.62%). Company insiders that own GoHealth stock include Anita Pramoda, Shane E Cruz and Travis J Matthiesen.
View institutional ownership trends for GoHealth.

GOCO stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Holocene Advisors LP, Squarepoint Ops LLC, Alyeska Investment Group L.P., Prana Capital Management LP, Schonfeld Strategic Advisors LLC, Price T Rowe Associates Inc. MD, and Blair William & Co. IL. Company insiders that have sold GoHealth company stock in the last year include Shane E Cruz, and Travis J Matthiesen.
View insider buying and selling activity for GoHealth or view top insider-selling stocks.

GOCO stock was bought by a variety of institutional investors in the last quarter, including River Road Asset Management LLC, The Manufacturers Life Insurance Company, Millennium Management LLC, BlackRock Inc., CWM LLC, Cannell Capital LLC, Credit Suisse AG, and Goldman Sachs Group Inc..
View insider buying and selling activity for GoHealth or or view top insider-buying stocks.

Shares of GOCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GOCO stock can currently be purchased for approximately $11.34.

GoHealth has a market capitalization of $3.64 billion and generates $877.35 million in revenue each year. The company earns $-44,270,000.00 in net income (profit) each year or $2.51 on an earnings per share basis.

GoHealth employs 3,067 workers across the globe.

The official website for GoHealth is www.gohealth.com.

GoHealth is headquartered at 214 WEST HURON STREET, CHICAGO IL, 60654.

GoHealth's mailing address is 214 WEST HURON STREET, CHICAGO IL, 60654. The company can be reached via phone at 312 386 8200 or via email at [email protected]